Related Experiment Video
Updated: Jun 5, 2026
06:19
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Disease modifying agents for multiple sclerosis.
Olga Hilas1, Priti N Patel, Sum Lam
1St. John's University College of Pharmacy and Allied Health Professions, Queens, NY, USA.
The Open Neurology Journal
|January 25, 2011
Summary
Disease modifying agents for multiple sclerosis (MS) show varied efficacy. Interferon beta is a primary treatment for relapsing-remitting MS, while newer agents offer promising future options.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic, complex neurological disease.
- Treatment of MS involves disease-modifying agents to manage symptoms and progression.
- Evaluating the efficacy and safety of these agents is crucial for patient care.
Purpose of the Study:
- To summarize clinical trial data on approved disease-modifying agents for multiple sclerosis.
- To assess the efficacy and safety profiles of various MS treatments.
- To identify emerging therapies for future multiple sclerosis management.
Main Methods:
- Comprehensive literature search of MEDLINE and clinicaltrials.gov.
- Inclusion of English-language articles from 1966 to August 2008.
- Evaluation of clinical relevance and evidence-based strength of identified studies.
Main Results:
- Interferon beta products demonstrate high efficacy in relapsing-remitting MS.
- Glatiramer and natalizumab are effective for relapsing MS; mitoxantrone suits advanced disease.
- Limited comparative data exists, but new agents show promise for future MS treatment.
Conclusions:
- Interferon beta remains a cornerstone therapy for many MS patients.
- Other agents are comparably effective in managing diverse MS types.
- Ongoing research into novel compounds offers hope for improved MS clinical management.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...